Skip to main content
Article thumbnail
Location of Repository

Characterisation and Mechanism of Bone Marrow Cell-Induced Myocardial Protection

By Vien Khach Lai

Abstract

It is controversial whether the administration of bone marrow cells (BMCs) can repair\ud the heart after an ischaemic insult and whether the mechanism of the putative beneficial\ud effect is due to a paracrine action. By using an experimental model of simulated\ud ischaemia of the atrial myocardium, I set up this thesis to understand the protective\ud properties of BMCs on the human myocardium with different clinical conditions and to\ud investigate the underlying mechanism. The results provide clear data that myocardial\ud protection of BMCs is dose-dependent with a maximal protection, comparable to that of\ud ischemic preconditioning, at a dose of ~1.5x106 cells/mg wet myocardium and that the\ud similar effect can be achieved when BMCs were present before, during or after\ud ischaemia. Allogeneic BMCs are as protective as the autologous cells and their capacity\ud is unaffected by frozen storage or culture, but lost by magnetic isolation. In addition, the\ud conditioned media, obtained after 30min of incubation of BMCs, can induce a\ud protection similar to that of BMCs, an effect that is abolished by selective blockade of\ud the insulin-like growth factor-1 receptor. Furthermore, disease states such as diabetes\ud and poor left ventricular function or the long-term administration of the mitochondrial\ud KATP channel opener nicorandil prevents the protective effect of BMCs, a consequence\ud that appears to be due to an alteration in the myocardium for diabetes and nicorandil and\ud mainly due to a defect in BMCs and also to a less responsive myocardium in heart\ud failure. A final clinical study aimed to elucidate the effect of BMCs during cardiac\ud surgery showed that BMCs have no additive protection to conventional cardioplegia\ud during coronary artery bypass grafting. In this thesis I have characterised the\ud cardioprotective potential of BMCs and identified some of the underlying mechanisms.\ud The results are of clinical interest and they should generate novel hypotheses

Publisher: University of Leicester
Year: 2010
OAI identifier: oai:lra.le.ac.uk:2381/9970

Suggested articles

Citations

  1. A controlled trial of ambroxol in chronic bronchitis.
  2. Absence of ischemic preconditioning protection in diabetic sheep hearts: Role of sarcolemmal KATP channel dysfunction.
  3. (1995). Acadesine extends the window of protection afforded by ischaemic preconditioning in conscious rabbits.
  4. Activation of cardiac progenitor cells reverses the failing heart senescent phenotype and prolongs lifespan.
  5. (1990). Acute myocardial dysfunction and recovery: a common occurrence after coronary bypass surgery.
  6. (1996). Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart.
  7. Administration of granulocyte colony-stimulating factor to recipients followed by intrabone marrow-bone marrow transplantation accelerates acceptance of allogeneic bone marrow cells in mice.
  8. Adult bone marrow-derived cells for cardiac repair: a systematic review and metaanalysis.
  9. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes.
  10. Adult cardiac stem cells are multipotent and support myocardial regeneration.
  11. (2005). Adult murine skeletal muscle contains cells that can differentiate into beating cardiomyocytes in vitro. PLoS Biol
  12. Aging impairs the beneficial effect of granulocyte colony-stimulating factor and stem cell factor on post-myocardial infarction remodeling.
  13. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart.
  14. (1998). al e. Energy metabolism after ischemic preconditioning in streptozotocin-induced diabetic rat hearts.
  15. (1997). Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia
  16. Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality.
  17. Altered calcium homeostasis in the pathogenesis of myocardial ischemic and hypoxic injury.
  18. Amiloride delays the ischemia-induced rise in cytosolic free calcium. Circulation research 1991;68:1250-1258.
  19. (1996). Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience.
  20. (1997). Apoptosis in human acute myocardial infarction. Circulation
  21. Apoptosis meets autophagy-like cell death in the ischemic penumbra: Two sides of the same coin?
  22. Apoptosis: a basic biological phenomenon with wideranging implications in human disease.
  23. Apoptosome formation and caspase activation: is it different in the heart?
  24. (2005). Are bone marrow stem cells plastic or heterogenous--that is the question. Exp Hematol
  25. (1996). ATP-sensitive potassium channels are altered in ventricular myocytes from diabetic rats.
  26. ATP-sensitive potassium channels: metabolic sensing and cardioprotection.
  27. (1998). Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation
  28. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review.
  29. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial.
  30. Autologous bone-marrow stem-cell transplantation for myocardial regeneration.
  31. Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias.
  32. Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects.
  33. (1999). Autologous transplantation of bone marrow cells improves damaged heart function. Circulation
  34. Autophagic programmed cell death by selective catalase degradation.
  35. Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling.
  36. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion.
  37. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction.
  38. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion.
  39. Bone marrow cells have a potent anti-ischemic effect against myocardial cell death in humans.
  40. Bone marrow cells regenerate infarcted myocardium.
  41. (1999). Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res
  42. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling.
  43. Bone marrow stromal cells (BMSCs) in bone engineering: limitations and recent advances.
  44. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation.
  45. brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways.
  46. but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy.
  47. c-kit dysfunction impairs myocardial healing after infarction.
  48. CABG and bone marrow stem cell transplantation after myocardial infarction.
  49. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction.
  50. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction.
  51. Cardiac side population cells exhibit endothelial differentiation potential. Exp Mol Med
  52. Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo.
  53. Cardiac stem cells and mechanisms of myocardial regeneration.
  54. Cardiac-specific ablation of the Na+-Ca2+ exchanger confers protection against ischemia/reperfusion injury.
  55. (1999). Cardiomyocytes can be generated from marrow stromal cells in vitro.
  56. Cardioprotection by postconditioning in conscious rats is limited to coronary occlusions <45 min.
  57. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines.
  58. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATPsensitive K+ channels. Possible mechanism of cardioprotection.
  59. (1995). Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion.
  60. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury.
  61. Caspase inhibitors promote alternative cell death pathways.
  62. (1998). Causative role of oxyradicals in myocardial stunning: a proven hypothesis. A brief review of the evidence demonstrating a major role of reactive oxygen species in several forms of postischemic dysfunction.
  63. CD31- but Not CD31+ cardiac side population cells exhibit functional cardiomyogenic differentiation.
  64. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction.
  65. Cellular mechanisms of ischemia-reperfusion injury.
  66. (1992). Changes in extracellular and intracellular pH in ischemic rabbit papillary muscle. Circ Res
  67. Characterization of an in vitro model for the study of the short and prolonged effects of myocardial ischaemia and reperfusion in man. Clin Sci (Lond)
  68. Chimerism of the transplanted heart.
  69. Clinically unrecognized ventricular dysfunction in young diabetic patients.
  70. Combining pharmacological mobilization with intramyocardial delivery of bone marrow cells overexpressing VEGF is more effective for cardiac repair.
  71. Concise review: stem cells, myocardial regeneration, and methodological artifacts.
  72. Control of cell survival by IGF signaling pathways.
  73. Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury.
  74. (1995). Defining ischaemia.
  75. Diabetes and the survival and recovery of the anoxic myocardium.
  76. Diabetic cardiomyopathy.
  77. (2006). Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol Cancer Ther
  78. Differentiation of circulating endothelial progenitor cells to a cardiomyogenic phenotype depends on E-cadherin.
  79. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium.
  80. Direct measurement of free radical generation following reperfusion of ischemic myocardium.
  81. Do stem cells in the heart truly differentiate into cardiomyocytes?
  82. Eat your heart out: Role of autophagy in myocardial ischemia/reperfusion.
  83. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.
  84. (1991). Effect of superoxide dismutase on infarct size and postischemic recovery of myocardial contractility and metabolism in dogs.
  85. Effect of superoxide dismutase on myocardial infarct size in the canine heart after 6 hours of regional ischemia and reperfusion: a demonstration of myocardial salvage.
  86. Effects of intracoronary autologous bone marrow cells on left ventricular function in acute myocardial infarction: a systematic review and meta-analysis for randomized controlled trials.
  87. Effects of long-term nicorandil administration on endothelial function, inflammation, and oxidative stress in patients without coronary artery disease.
  88. (1991). Effects of superoxide dismutase on reperfusion arrhythmias and left ventricular function in patients undergoing thrombolysis for anterior wall acute myocardial infarction.
  89. Electromechanical coupling between skeletal and cardiac muscle. Implications for infarct repair.
  90. Endothelial progenitor cells: past, state of the art, and future.
  91. Enhancing macroautophagy protects against ischemia/reperfusion injury in cardiac myocytes.
  92. Enhancing repair of the mammalian heart.
  93. Errors in the measurement of cardiac output by thermodilution.
  94. Evidence for mitochondrial K+ channels and their role in cardioprotection.
  95. (1993). Evidence of oxidative stress in chronic heart failure in humans.
  96. Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil.
  97. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement.
  98. Evidence that human cardiac myocytes divide after myocardial infarction.
  99. Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity. American journal of physiology Heart and circulatory physiology
  100. Failure to precondition pathological human myocardium.
  101. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes.
  102. Generation of functional cardiomyocytes from adult mouse spermatogonial stem cells.
  103. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium.
  104. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts.
  105. (1988). Hearts from diabetic rats are more resistant to in vitro ischemia: possible role of altered Ca2+ metabolism. Circ Res
  106. Heterogeneic nature of adult cardiac side population cells.
  107. High passage number of stem cells adversely affects stem cell activation and myocardial protection.
  108. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart.
  109. Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism.
  110. ICE-ing the heart.
  111. IGF-I differentially regulates Bcl-xL and Bax and confers myocardial protection in the rat heart.
  112. IGF1 activates PKC alpha-dependent protein synthesis in adult rat cardiomyocytes.
  113. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction.
  114. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials.
  115. Impaired potency of bone marrow mononuclear cells for inducing therapeutic angiogenesis in obese diabetic rats.
  116. Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment.
  117. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial.
  118. In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function.
  119. Incidence and epidemiology of heart failure.
  120. Inflammatory responses after intracoronary injection of autologous mononuclear bone marrow cells in patients with acute myocardial infarction.
  121. (2003). Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol
  122. (1993). Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study.
  123. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning.
  124. (2000). Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation
  125. (1994). Inhibitors of Ca2+ ATPase pump of sarcoplasmic reticulum attenuate reperfusion stunning in isolated rat heart.
  126. (1999). Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease.
  127. Insulin-like growth factor type 1 prevents hyperglycemia-induced uncoupling protein 3 downregulation and oxidative stress.
  128. (2001). Insulin-like growth factor-1 improves postischemic recovery in hypertrophied hearts. Ann Thorac Surg
  129. Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury.
  130. Insulin-like growth factor-I improves recovery of cardiac performance during reperfusion in isolated rat heart by a wortmannin-sensitive mechanism.
  131. Insulin-like growth factor-I rapidly activates multiple signal transduction pathways in cultured rat cardiac myocytes.
  132. (1997). Insulin-like growth factor-II delays myocardial infarction in experimental coronary artery occlusion. Cardiovasc Res
  133. (1997). Intracellular ATP levels determine cell death fate by apoptosis or necrosis.
  134. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial.
  135. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial.
  136. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.
  137. Intracoronary infusion of CD133+ and CD133-CD34+ selected autologous bone marrow progenitor cells in patients with chronic ischemic cardiomyopathy: cell isolation, adherence to the infarcted area, and body distribution.
  138. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety.
  139. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction.
  140. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies.
  141. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia.
  142. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury.
  143. (1993). Ischaemic preconditioning--time course of renewal in the pig. Cardiovasc Res
  144. (1999). Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization.
  145. Ischemic preconditioning alters real-time measure of O2 radicals in intact hearts with ischemia and reperfusion.
  146. (1990). Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res
  147. Ischemic tolerance of rat hearts in acute and chronic phases of experimental diabetes.
  148. (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.
  149. (1995). L-carnitine increases glucose metabolism and mechanical function following ischaemia in diabetic rat heart. Cardiovasc Res
  150. Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation: effects of marrow dose.
  151. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.
  152. Little evidence for developmental plasticity of adult hematopoietic stem cells.
  153. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function.
  154. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms.
  155. Long-term administration of nicorandil abolishes ischemic and pharmacologic preconditioning of the human myocardium: role of mitochondrial adenosine triphosphate-dependent potassium channels.
  156. Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction.
  157. Lysosomal alterations in hypoxic and reoxygenated hearts. II. Immunohistochemical and biochemical changes in cathepsin D.
  158. Management of acute graft-versus-host disease.
  159. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages.
  160. Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury.
  161. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury.
  162. (1998). Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. Circulation
  163. Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium.
  164. (1926). Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 2002;73:1919-1925; discussion
  165. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts.
  166. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation.
  167. (2008). Mitochondria as a Target for the Cardioprotective Effects of Nitric Oxide in Ischemia–Reperfusion Injury. Antioxidants & Redox Signaling
  168. Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium.
  169. (1999). Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res
  170. Mitochondrial involvement in IGF-1 induced protection of cardiomyocytes against hypoxia/reoxygenation injury.
  171. Mobilized bone marrow cells repair the infarcted heart, improving function and survival.
  172. (2001). Modulation of sarcoplasmic reticulum function: a new strategy in cardioprotection? Pharmacol Ther
  173. Moibenko AA. Protective effect of autophagy in anoxia-reoxygenation of isolated cardiomyocyte?
  174. (1999). Molecular and cellular mechanisms of myocardial stunning.
  175. Molecular regulation of autophagy and apoptosis during ischemic and non-ischemic cardiomyopathy.
  176. Monitoring of bone marrow cell homing into the infarcted human myocardium.
  177. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor.
  178. (1996). Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care
  179. Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification.
  180. (1977). Myocardial function and coronary blood flow response to acute ischemia in chronic canine diabetes. Circ Res
  181. Myocardial ischemia and reperfusion injury.
  182. (1990). Myocardial mechanics in young adult patients with diabetes mellitus: effects of altered load, inotropic state and dynamic exercise.
  183. Myocardial reperfusion injury.
  184. (1998). Myocyte cell death in the diseased heart. Circ Res
  185. Myogenic specification of side population cells in skeletal muscle.
  186. Necrotic death as a cell fate.
  187. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function.
  188. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury.
  189. (1997). Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation
  190. (1997). Overexpression of insulinlike growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy.
  191. (1991). Oxygen free radicals and congestive heart failure.
  192. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg 2005;80:229-236; discussion
  193. (2008). Paracrine effects of cell transplantation: strategies to augment the efficacy of cell therapies. Semin Thorac Cardiovasc Surg
  194. Paracrine effects of direct intramyocardial implantation of bone marrow derived cells to enhance neovascularization in chronic ischaemic myocardium.
  195. Paracrine mechanisms in adult stem cell signaling and therapy.
  196. (1996). Paradoxical effect of ischemic preconditioning on ischemic contracture? NMR studies of energy metabolism and intracellular pH in the rat heart.
  197. Past and present course of cardioprotection against ischemia-reperfusion injury.
  198. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart.
  199. Pharmacological and ischemic preconditioning of the human myocardium: mitoKATP channels are upstream and p38MAPK is downstream of PKC.
  200. Pharmacological preconditioning with diazoxide slows energy metabolism during sustained ischemia.
  201. Plasticity and tissue regenerative potential of bone marrow-derived cells.
  202. Plasticity of bone marrow-derived stem cells.
  203. Pluripotency of mesenchymal stem cells derived from adult marrow.
  204. Postconditioning: old wine in a new bottle?
  205. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages.
  206. (2008). Potency and Mechanism of Bone Marrow Cells-Induced Cardioprotection. Circulation,
  207. Potential risks of bone marrow cell transplantation into infarcted hearts.
  208. (2008). Preconditioning and postconditioning: new strategies for cardioprotection. Diabetes Obes Metab
  209. Preconditioning and postconditioning: united at reperfusion.
  210. Preconditioning the diabetic heart: the importance of Akt phosphorylation.
  211. Preconditioning the human myocardium by simulated ischemia: studies on the early and delayed protection.
  212. Preconditioning the myocardium: from cellular physiology to clinical cardiology.
  213. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.
  214. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial).
  215. Protection Against Ischemia-Induced Ventricular Arrhythmias and Myocardial Dysfunction Conferred by Preconditioning in the Rat Heart: Involvement of Mitochondrial KATP Channels and Reactive Oxygen Species.
  216. Protection of the human heart with ischemic preconditioning during cardiac surgery: role of cardiopulmonary bypass.
  217. (1994). Protective effects of the SOD-mimetic SC-52608 against ischemia/reperfusion damage in the rabbit isolated heart.
  218. (2008). Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nat Clin Pract Cardiovasc Med
  219. Reactive oxygen species, but not Ca2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion.
  220. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial.
  221. (1998). Regenerating functional myocardium: improved performance after skeletal myoblast transplantation.
  222. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells.
  223. Regulation of apoptosis by insulin-like growth factor (IGF)-I.
  224. (1997). Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation
  225. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans.
  226. (2006). Repair of the damaged heart by bone marrow cells: from experimental evidence to clinical hope. Ann Thorac Surg
  227. (1996). Reperfusion injury on cardiac myocytes after simulated ischemia.
  228. (2007). Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev
  229. Reperfusion injury: does it exist?
  230. (2001). Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ Res
  231. Role of adult bone marrow stem cells in the repair of ischemic myocardium: current state of the art.
  232. Role of clinical pathologies in myocardial injury following ischaemia and reperfusion.
  233. (2008). Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair
  234. Selective mitochondrial adenosine triphosphate-sensitive potassium channel activation is sufficient to precondition human myocardium.
  235. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study.
  236. (2002). Side population cells from diverse adult tissues are capable of in vitro hematopoietic differentiation. Exp Hematol
  237. Skeletal myoblast for cell therapy.
  238. (1996). Skeletal myoblast transplantation for repair of myocardial necrosis.
  239. (1999). Sodium regulation during ischemia versus reperfusion and its role in injury. Circ Res
  240. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells.
  241. Stem cell plasticity.
  242. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function.
  243. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization.
  244. Stromal cellderived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury.
  245. (1992). Subcellular electrolyte alterations during progressive hypoxia and following reoxygenation in isolated neonatal rat ventricular myocytes. Circ Res
  246. (1991). Superoxide dismutase conjugated to polyethylene glycol fails to limit myocardial infarct size after 30 min ischemia followed by 72 h of reperfusion in the rabbit.
  247. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study.
  248. (2008). Targeting the mitochondria to augment myocardial protection. Current Opinion in Pharmacology
  249. (2006). The Atlas of Heart Disease and Stroke. The World Health Organization
  250. The diabetic heart is more sensitive to ischemic injury.
  251. The inflammatory response in myocardial infarction.
  252. (1999). The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res
  253. The mitochondrial permeability transition pore and ischemiareperfusion injury.
  254. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation.
  255. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial.
  256. (1999). The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res
  257. The role of the sca-1+/CD31- cardiac progenitor cell population in postinfarction left ventricular remodeling.
  258. (2000). The role of tumor necrosis factor alpha in the pathophysiology of congestive heart failure. Curr Cardiol Rep
  259. The sarcoplasmic reticulum as the primary target of reperfusion protection.
  260. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia.
  261. Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection.
  262. Timing of intracoronary bone-marrow-derived stem cell transplantation after ST-elevation myocardial infarction.
  263. TNF-alpha gene promoter polymorphism at nucleotide -308 and the inflammatory response and oxidative stress induced by cardiac surgery: role of heart failure and medical treatment.
  264. (2007). Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circ Res
  265. Transcoronary transplantation of progenitor cells after myocardial infarction.
  266. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes.
  267. Transplanted adult bone marrow cells repair myocardial infarcts in mice.
  268. (1950). Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study,
  269. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction.
  270. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism.
  271. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.